Abstract Background. Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients. Materials and Methods. This was an observational study enrolling HIV-1-infected, virologically suppressed patients switching to lamivudine plus dolutegravir. We performed Kaplan-Meyer survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1,000 copies/mL or by two consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (TD, defined as the interruption of either 3TC or DTG), Cox-regression to assess predictors and linear mixed model for repeated measures to measure changes in immunological and metabolic parameters. Results. Five-hundred fifty-six patients were eligible for the analysis: median CD4+ count at baseline was 668 cell/mm3, while median time of virological suppression was 88 months. Estimated probabilities of maintaining virological suppression at weeks 96 and 144 were 97.5% (SD ±0.8) and 96.5% (SD ±1.0). Years from HIV diagnosis were the only predictor of VF. In patients with time of virological suppression <88 months, the rate of VF was higher in the presence of the M184V mutation. Estimated probabilities of remaining on 3TC+DTG at 96 and 144 weeks were 79.2% (SD ±1.9) and 75.2% (SD ±2.2). A significant increase in CD4 cell count (+44 cell/mm3, p=0.015), CD4/CD8 ratio (+0.10, p=0.002) and HDL cholesterol (+5.4 mg/dl, p=0.036) was found after 144 weeks; meanwhile total cholesterol (-9.1 mg/dl, p=0.007) and triglycerides (-2.7, p=0.009) significantly decreased. Conclusions. Our findings confirm the efficacy and tolerability of 3TC+DTG in virologically suppressed patients.
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients / Gianmaria, Baldin; Arturo, Ciccullo; Stefano, Rusconi; Amedeo, Capetti; Gaetana, Sterrantino; Manuela, Colafigli; D'Ettorre, Gabriella; Andrea, Giacometti; Maria Vittoria, Cossu; Borghetti, Alberto; William, Gennari; Cristina, Mussini; Vanni, Borghi; Simona Di, Giambenedetto. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - 54:6(2019), pp. 728-734. [10.1016/j.ijantimicag.2019.09.002]
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients
Gabriella D’EttorreConceptualization
;BORGHETTI, ALBERTO;
2019
Abstract
Abstract Background. Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients. Materials and Methods. This was an observational study enrolling HIV-1-infected, virologically suppressed patients switching to lamivudine plus dolutegravir. We performed Kaplan-Meyer survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥1,000 copies/mL or by two consecutive HIV-RNA ≥ 50 copies/mL) and treatment discontinuation (TD, defined as the interruption of either 3TC or DTG), Cox-regression to assess predictors and linear mixed model for repeated measures to measure changes in immunological and metabolic parameters. Results. Five-hundred fifty-six patients were eligible for the analysis: median CD4+ count at baseline was 668 cell/mm3, while median time of virological suppression was 88 months. Estimated probabilities of maintaining virological suppression at weeks 96 and 144 were 97.5% (SD ±0.8) and 96.5% (SD ±1.0). Years from HIV diagnosis were the only predictor of VF. In patients with time of virological suppression <88 months, the rate of VF was higher in the presence of the M184V mutation. Estimated probabilities of remaining on 3TC+DTG at 96 and 144 weeks were 79.2% (SD ±1.9) and 75.2% (SD ±2.2). A significant increase in CD4 cell count (+44 cell/mm3, p=0.015), CD4/CD8 ratio (+0.10, p=0.002) and HDL cholesterol (+5.4 mg/dl, p=0.036) was found after 144 weeks; meanwhile total cholesterol (-9.1 mg/dl, p=0.007) and triglycerides (-2.7, p=0.009) significantly decreased. Conclusions. Our findings confirm the efficacy and tolerability of 3TC+DTG in virologically suppressed patients.File | Dimensione | Formato | |
---|---|---|---|
Baldin_Long-term-data_postprint_2019.pdf
accesso aperto
Tipologia:
Documento in Post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
817.33 kB
Formato
Adobe PDF
|
817.33 kB | Adobe PDF | |
Baldin_Long-term-data_2019.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
704.7 kB
Formato
Adobe PDF
|
704.7 kB | Adobe PDF | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.